Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
Sagimet Biosciences, the strategic partner of Ascletis Pharma, has successfully dosed the first patient in a pivotal Phase III U.S. clinical trial evaluating denifanstat for moderate to severe acne. This milestone advances the therapeutic candidate closer to potential commercialization.
Clinical-stage biopharmaceutical company Sagimet Biosciences announced the administration of the first dose in its Phase III trial for denifanstat, also known as ASC40. The trial evaluates the efficacy and safety of the oral drug in treating patients suffering from moderate to severe acne vulgaris. This clinical advancement triggers a strategic milestone under the ongoing partnership between Sagimet and Ascletis Pharma. Positive clinical data from this late-stage study could pave the way for future regulatory submissions in major pharmaceutical markets. Investors in both partnering entities responded favorably to the operational progress in the dermatology pipeline. The trial represents a significant step in addressing unmet medical needs in chronic skin conditions through novel metabolic mechanisms.
إخلاء مسؤولية تحليل الذكاء الاصطناعي
يُنشأ تحليل التأثير على الأصول بواسطة الذكاء الاصطناعي ولأغراض معلوماتية فقط. ولا يُعد نصيحة مالية. أجرِ بحثك الخاص دائمًا قبل اتخاذ قرارات الاستثمار.
النقاش